A1 Refereed original research article in a scientific journal

Adenosine A2A receptors in secondary progressive multiple sclerosis: a [C-11]TMSX brain PET study




AuthorsRissanen E, Virta JR, Paavilainen T, Tuisku J, Helin S, Luoto P, Parkkola R, Rinne JO, Airas L

PublisherNATURE PUBLISHING GROUP

Publication year2013

JournalJournal of Cerebral Blood Flow and Metabolism

Journal name in sourceJOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Journal acronymJ CEREBR BLOOD F MET

Number in series9

Volume33

Issue9

First page 1394

Last page1401

Number of pages8

ISSN0271-678X

DOIhttps://doi.org/10.1038/jcbfm.2013.85


Abstract
In this study, positron emission tomography (PET) imaging with a radioligand to adenosine A2A receptors (A2AR)-a potent regulator of inflammation-was used to gain insight into the molecular alterations in normal-appearing white matter (NAWM) and gray matter (GM) in secondary progressive multiple sclerosis (SPMS). Normal-appearing white matter and GM, despite seeming normal in conventional mangnetic resonance imaging (MRI), are important loci of widespread inflammation, neuronal damage, and source of progressive disability in multiple sclerosis (MS). Dynamic PET imaging using A2AR-specific [C-11]TMSX and brain MRI with diffusion tensor imaging were performed to eight SPMS patients and seven healthy controls. Distribution volumes (V-T) of [C-11]TMSX were analyzed from 13 regions of interest using Logan plot with arterial plasma input. The SPMS patients had significantly increased [C-11]TMSX-VT in NAWM compared with controls (mean (s.d.): 0.55 (+/- 0.08) vs. 0.45 (+/- 0.05); P = 0.036). Both the increased VT and the decreased fractional anisotropy (FA) in NAWM were associated with higher expanded disability status scale (EDSS) scores (P = 0.030 and P = 0.012, respectively), whereas the T2-lesion load of SPMS patients did not correlate with EDSS. This study shows, that A2ARs are increased in the brain of SPMS patients, and that [C-11]TMSX-PET provides a novel approach to learn about central nervous system pathology in SPMS in vivo.



Last updated on 2024-26-11 at 14:37